Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Non-Current Liabilities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Total Non-Current Liabilities for 13 consecutive years, with $182.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 10.27% to $182.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $182.5 million, a 10.27% increase, with the full-year FY2024 number at $176.7 million, changed N/A from a year prior.
  • Total Non-Current Liabilities was $182.5 million for Q3 2025 at Theravance Biopharma, down from $199.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $746.3 million in Q1 2021 to a low of $89.6 million in Q4 2022.
  • A 5-year average of $330.9 million and a median of $176.7 million in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: crashed 77.58% in 2023, then rose 22.14% in 2025.
  • Theravance Biopharma's Total Non-Current Liabilities stood at $724.1 million in 2021, then tumbled by 87.63% to $89.6 million in 2022, then surged by 78.33% to $159.8 million in 2023, then grew by 10.61% to $176.7 million in 2024, then increased by 3.25% to $182.5 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Total Non-Current Liabilities are $182.5 million (Q3 2025), $199.6 million (Q2 2025), and $176.3 million (Q1 2025).